Affymax Prices Above Range

Affymax Inc., a Palo Alto, Calif.-based drug development company, priced 3.7 million common shares at $25 per share, for an IPO take if approximately $92.5 million. The original forecast had been for 3.5 million shares to be sold at between $22 and $24 per share. It will trade on the Nasdaq under ticker symbol AFFY, while Morgan Stanley served as lead underwriter. Affymax had raised around $160 million in VC funding since its 2001 inception, from firms like Apax Partners, MPM Capital, Sprout Group, Jafco, Bear Stearns Health Innoventures and Bessemer Venture Partners.< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />